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Several new drugs have recently been developed for the treatment of tuberculosis (TB) and, together with a 
number of repurposed drugs, are currently in clinical trials. The challenge remains to determine which of these 
novel compounds to prioritize, and to identify which drug combinations will be most effective. The task of testing 
each novel drug in combination with both new and existing antitubercular compounds using conventional 
methodologies is an expensive and daunting prospect. There is a need therefore for new assays to characterize 
drug efficacy, which are both robust and rapid, and which predict a superior regimen in combination drug 
therapy. In this chapter we discuss the use of gene expression profiling as a tool in the tuberculosis drug discovery 
pipeline, and the application of RNA-based assays for monitoring treatment success. 
 
Current tuberculosis drug discovery & development 
The drug development pipeline for TB has been fuelled over the past 10 years by an explosion of new 
antitubercular chemical entities that have been dis- covered, or rediscovered as existing drugs are repurposed for 
TB. This is welcome and long-overdue since the last systematic introduction of TB- specific drugs was almost 50 
years ago [1]. Many of the new drugs are undergoing clinical trials to evaluate their efficacy in combination 
therapies to treat fully drug-sensitive TB, and/or multi or extensively drug-resistant TB (MDR or XDR-TB). For up-
to-date information about the TB drug discovery pipeline visit the ’Working Group on New TB Drugs’ website [2]. 
One of these new TB drugs, bedaquiline (formerly TMC207), has recently been approved by the US Food and Drug 
Administration (FDA) to be added to the treatment regimen of adult pulmonary MDR-TB. Furthermore, delamanid 
another novel chemical entity with antitubercular activity has been conditionally approved by the European 
Medicines Agency (EMA) for use in drug resistant TB. 
 
Of the TB drugs that are currently in clinical trials, many are either new chemical entities derived from high-
throughput whole cell screening assays, or are drugs that have not been traditionally used against TB but which 
are now being evaluated in combination with current anti-TB drugs (Table 6.1). For example, the nitroimidazol, 
pretomanid (PA-824), a new chemical entity currently under Phase III clinical trials, was discovered by screening a 
series of chemically-modified bicyclic nitroimidazoles derived originally from an anti- cancer hit molecule against 
Mycobacterium tuberculosis [3]. Pretomanid, with novel mechanism(s) of action is active against different 
physiological states of M. tuberculosis [4]. Early bactericidal activity (EBA) studies of pretomanid in combination 
with moxifloxacin and pyrazinamide showed good efficacy against drug-susceptible TB [5]. Furthermore, the same 
combination demonstrated significantly greater and faster bactericidal activity compared to standard anti-
tuberculosis treatment in phase IIb trials [6]. In an alternative strategy, the fluoroquinolones exemplify an existing 
class of drugs that have been re-evaluated for their ability to kill M. tuberculosis. Fluoroquinolones are a family of 
antibiotics active against a broad-spectrum of bacteria including mycobacteria, which act by inhibiting DNA 
topoisomerase and DNA replication. The efficacy of moxifloxacin, an antibiotic from this group, was recently 
assessed in a phase III clinical trial, REMOxTB. This noninferiority clinical trial in patients with drug-susceptible M. 
tuberculosis was designed to identify whether substitution of either isoniazid or ethambutol for moxifloxacin was 
able to reduce treatment time from the current 6 months to a proposed 4 months [7]. Novel drug combinations 
from this clinical trial failed to pass the non-inferiority threshold highlighting that the addition of moxifloxacin to 
the current regimen is not enough to reduce the treatment duration to 4 months from the current requirement of 
6 months [8]. Nevertheless, the REMOxTB trial demonstrated the successful use of a fluoroquinolone in TB 
treatment. Moxifloxacin is now part of the phase III trial, STAND, where a combination of pretomanid, 
moxifloxacin and pyrazinamide will be evaluated against both drug-susceptible and MDR-TB cases. 
 
  
 
Table 6.1. New possible additions to the antituberculosis drug portfolio. 
 
 
Drug  Existing drug class Mechanism of 
action (MoA)  
Methods used for 
elucidating MoA 
Development stage 
Pretomanid 
(PA-824) 
New chemical entity 
(NCE) 
Mycolic acid 
biosynthesis, 
respiratory chain, 
multiple targets 
Transcriptomics and 
metabolomics 
Phase III 
Benzothiazinones NCE Arabinan synthesis Transcriptomics, 
proteomics and 
genetic mutation 
studies 
Preclinical 
Sutezolid Oxazolidinone Protein synthesis; 
23S rRNA 
Cellular translation 
assays 
Phase II 
SQ109 NCE Cell wall inhibition; 
MmpL3 
Genetic mutation 
studies 
Phase II 
Linezolid Oxazolidinone Protein synthesis; 
23S rRNA 
Metabolomics Phase II 
Rifapentine Rifamycin Translation Metabolomics Phase II and Phase 
III 
Bedaquiline 
(TMC207) 
NCE ATP synthesis Metabolomics, 
genetic mutation 
studies 
Phase II and Phase 
III 
AZD5847 Oxazolidinone Protein synthesis; 
23S rRNA 
Cellular translation 
assays 
Phase II 
Delamanid 
(OPC-67683) 
NCE Mycolic acid 
synthesis inhibition 
Metabolomics Phase III 
Fluoroquinolones 
(gatifloxacin and 
moxifloxacin) 
 
Repurposed DNA replication and 
transcription; DNA 
gyrase, 
topoisomerase IV 
Genetic mutation 
studies 
Phase III 
Q203 NCE ATP synthesis; 
cytochrome bc1 
complex 
Genetic mutation 
studies 
Preclinical 
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TB is treated using combination therapy to achieve sterilization and to minimize the occurrence of drug 
resistance; the standard therapy regimen for drug-sensitive TB involves taking combinations of four drugs 
(isoniazid, rifampicin, ethambutol and pyrazinamide) over a period of 6 months. This provides a challenge for the 
design of clinical trials as new drugs need to be somehow prioritized and tested in novel combinations. Current 
solutions either modify standard TB chemotherapy by addition or replacement of an existing drug with a newly 
developed drug, or generate completely novel regimens. Innovative study design with multiarm, multistage trials 
where different combinations are tested alongside the standard treatment are also proposed [1]. Allied to the 
success of these trials is the ability to gauge the efficacy of new TB treatments in a short period of time. EBA 
studies measure the success of drug combinations by determining their bactericidal activity during the first two 
weeks of treatment. These studies rely on microbiological culture and therefore the readout can take up to 6 
weeks due to the slow growth rate of M. tuberculosis. In addition, EBA studies of multiple combinations of drugs 
may be difficult to interpret; for example pyrazinamide, essential to the success of current regimens, does not 
have any antimicrobial effect in the first 2 days of treatment, but reduces bacterial numbers in sputum over the 
next 12 days [9]. Thus, there is an urgent need for new assays to monitor drug efficacy that may also help to 
characterize the action of novel drugs and drug combinations in vivo. Consortia such as PreDiCT-TB [10] are 
aiming to support this gap by generating and evaluating new decision making tools based on modelling in vitro, in 
vivo and clinical trials datasets to select successful future drug combinations. In such approaches, bacterial 
transcriptomics as unbiased assays are useful to map the changing state of TB bacilli after drug exposure. 
 
 
Transcriptomic analysis for understanding drug mode of action 
Many of the inhibitors currently under clinical development were identified using whole cell assays where the 
effect of compounds on bacterial killing is measured directly. This approach has proved particularly successful in 
mycobacterial research, where simply getting a novel chemical entity across the relatively impermeable 
mycobacterial cell wall is a triumph. However, the mechanism of action of these inhibitors at this stage is usually 
unknown. Understanding how a drug kills bacteria and identifying the molecular tar- get(s) is vital to improve drug 
efficacy and reduce cytotoxicity. In addition, understanding the mode of drug action also allows potential drug 
resistance mechanisms to be recognized, such as mutations to rpoB associated with rifampicin resistance. Two 
genome-wide methodologies are often employed to help define the class of action of a novel compound. The first 
is to identify mutations that lead to drug resistance; spontaneous drug-resistant bacterial mutants are generated 
in the laboratory and molecular methods employed to identify the mutated genes which may include the drug 
target. Nowadays, the genomes of resistant mutants are sequenced using next generation sequencing 
technologies to identify putative targets [11], or define factors that affect drug efficacy. However, this method is 
only feasible if resistant mutants can be successfully produced, which may not be possible for all categories of 
chemical [12]. In addition, the mutated gene(s) may not always determine the site of drug action, as in the case of 
prodrugs where often the activating enzyme is distinguished. 
 
The second global approach, which is useful to apply before focused enzyme inhibition and drug-binding assays 
are developed for target definition, is transcriptional profiling the response of bacilli to new chemical entities. 
Transcriptome studies can provide useful insights into the target pathways affected by drug action, as well as 
decipher the differential regulation of processes that may influence drug efficacy. Conventionally, microarrays or 
qRT-PCR panels, and more recently RNAseq, have been employed to elucidate the class of action of novel 
inhibitors. Drugs with similar modes of action exert comparable stresses on bacilli which result in equivalent 
transcriptional responses to drug exposure. Thus, the transcriptional signature from a novel compound may be 
dissected by mapping the differentially expressed genes onto a genome-wide interpretive framework of 
transcriptional responses generated from the exposure of M. tuberculosis bacilli to numerous antimicrobials and 
inhibitors [13-15]. Evidence from such studies has aided the identification of targets for the benzothiazinones [16] 
and pretomanid [4]. In addition, meta-analysis of transcriptomics data derived from bacteria exposed to drugs 
alone or in combination may signpost the contribution of each constituent drug to the efficacy of that particular 
regimen. This approach has been applied to eukaryotes to generate a drug action network where the location of 
each drug in the network is dependent upon the drug-induced differential gene expression signature [17]. Using 
this net- work, the mode of action of a new compound can be identified alongside defining a new function to a 
previously studied drug. A similar methodology might also be applied to antitubercular drugs using the genome-
wide transcriptional datasets that are already available. 
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Understanding the action of drugs in combination & in vivo 
Defining single drug action in vitro is a complex but well-trodden path; how- ever understanding how 
combinations of drugs act on bacilli residing in multiple physiological niches during infection is an enormous 
challenge. Bacteria in vivo likely adapt to the microenvironments that surround them, and this may lead to the 
generation of subpopulations of bacilli responding to different stimuli or growth conditions. These disparate 
bacterial phenotypic states may alter the ability of drugs to kill bacilli; specific bacterial populations may become 
exquisitely sensitive or tolerant to the action of a drug. For example, nonreplicating cells are likely to be tolerant 
to drugs that target processes which are not essential in nongrowing cells, such as DNA replication and cell wall 
biosynthesis pathways that are critically important in replicating bacilli. Different bacterial physiological states, 
generated in vitro and after infection, have been mapped extensively using transcriptional profiling [18-21]. Such 
mRNA profiling studies promise to reveal metabolic pathways that may be amiable to novel drug design, such as 
lipid metabolism pathways induced by TB bacilli in macrophages. Additionally, temporal patterns of gene 
expression have defined the transition between actively replicating mycobacterial populations and persister-like 
states [22,23]. Thus, it is possible (in some in vitro and animal model scenarios) to predict the tolerance of bacilli 
to drug exposure, and thus the efficacy of a drug on a specific population, from examining the bacterial 
transcriptional signature. For example, the lack of induction of INH-responsive genes in a murine model of 
infection after INH-exposure suggested that these bacilli were likely tolerant to isoniazid killing [24]. It is 
important therefore in novel drug discovery programs that several different models that capture the various 
physiological states of M. tuberculosis bacilli found in human disease (for example; actively replicating, viable but 
nonreplicating, low metabolic activity) are tested in order to comprehensively assay the potential impact of new 
inhibitors. Moreover, the characterization of bacilli during infection by transcriptional profiling also enables in 
vitro systems to be developed that test the efficacy of novel compounds in scenarios that mimic the multiple 
environments that may be encountered by bacilli during disease. 
 
Another important issue that must be addressed in both preclinical and clinical studies is to recognize whether a 
new inhibitor will act well in combination with existing drugs and/or in new combinations of anti-TB drugs. In 
preclinical studies, this is usually tested using a synergism or checker- board assay where two drugs are tested in 
combination and their Fractional Inhibitory Concentration Index (FICI) is calculated. This class of assay deter- 
mines whether there is a synergetic, an antagonistic or an indifferent effect in vitro. However, a synergistic in 
vitro effect may not be maintained in vivo, or an in vivo antagonistic effect may not be observed in vitro. For 
example, murine models of tuberculosis demonstrate antagonism between isoniazid and pyrazinamide, two first-
line antituberculosis drugs, which was not identified in vitro since it is difficult to demonstrate pyrazinamide 
killing in most in vitro models [25]. Gene expression profiling may be utilized to define the efficacy of a drug 
combination by mapping the specific profile of a drug combination and comparing it to the gene profiles of each 
constituent drug. The presence of a drug-specific signature likely indicates some action of the drug, and a positive 
contribution to the regimen. Conversely, drugs that do not elicit a transcriptional response in combination 
therapy may not be enhancing bacterial killing in the specific model evaluated. A cancer study of lymphoma and 
tumour cells treated with a variety of anticancer drugs individually and in combination revealed, using RNAi 
technology, that targeting the expression of eight genes was sufficient to predict the mode of action of single 
drugs alone as well as their combinatory effect [26]. The same methodology was also able to recognize whether a 
drug combination represented an average of single drug effects, a signature dominated by one of the drugs, or a 
completely new profile uncovering a combinatory mode of action [26]. Thus, transcriptional profiling the effect of 
combinations of drugs in settings that mirror the mixed populations of bacteria found in vivo may highlight 
unseen synergetic or antagonistic effects between drugs targeting bacteria with equivalent or disparate 
phenotypes. 
 
 
Molecular markers for monitoring treatment success in tuberculosis 
It is vitally important to effectively and efficiently monitor responses to treatment during TB chemotherapy in 
order to successfully eradiate TB bacilli, avoid relapse and prevent the emergence of drug resistance. 
Furthermore, active treatment outcome measures give the physician the opportunity to adjust or enhance drug 
regimens on a patient-by-patient basis selecting the most appropriate combination of drugs. At present, the gold 
standard for TB treatment is liquid culture conversion after two months of chemotherapy, symbolising a target 
date where TB bacilli can no longer be cultured from patient sputum. In addition, smear microscopy and serial 
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sputum colony counts are also employed for determining drug regimen efficacy. These classic microbiological 
measures currently act as predictive markers for treatment success. However, with the exception of smear 
microscopy, these methods require bacterial culture and because the growth rate of M. tuberculosis is slow, the 
turnaround time of these assays is long (weeks/months; 52 days for liquid MGIT cultures to be defined as 
negative). This restricts the ability of physicians to quickly amend treatment regimens and may influence 
treatment outcomes, especially when managing MDR-TB cases. Thus, new biomarkers are needed to monitor 
treatment and provide predictive outcomes soon after the start of chemotherapy, overcoming the limitations of 
the current methods where either the detection limit is low or the assay time is long. The lack of reliable 
prognostic biomarkers for drug efficacy and relapse is also hampering the design and performance of current 
clinical trials [1]. It is worth noting that individualized medicine for monitoring TB therapy is not likely to be 
relevant yet for the vast majority of TB patients who are in resource-poor settings. However, this approach is 
highly relevant to clinical trials where, for example, whole genome sequencing methods are employed to 
distinguish between patient relapse or reinfection. The discovery and development of indicative biomarkers will 
therefore help to support decision making policies in multi-regimen trials where the efficacy of novel drug 
combinations is under investigation. 
 
The application of molecular-based culture-free assays would be a great advantage for monitoring treatment as 
the turnaround time should be significantly faster, meaning that results will be available sooner for health 
physicians to manage or start appropriate treatment [27]. These assays are usually PCR-based tests where the 
mycobacterial DNA or RNA is measured and converted into simple positive or negative scores. This is exemplified 
by the introduction of the GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA) which has revolutionized the 
diagnosis of TB by detecting the rpoB gene from M. tuberculosis in sputum and bronchoalveolar lavage samples 
[28]; TB diagnosis being a distinct but related problem to measuring treatment outcomes. The GeneXpert 
MTB/RIF assay detects the presence of M. tuberculosis DNA in sputum samples as well as screening for rpoB gene 
mutations which are associated with rifampicin resistance and MDR-TB. The rapid 2 h assay time of this molecular 
method allows treatment to start directly after diagnosis and to be refined to the drug resistance background of 
the TB clinical isolate. This compares to classical microbiological-based drug susceptibility tests that may take over 
two weeks to obtain results. This time shift from 2 weeks or more to 2 h is possible due to the switch from micro- 
biological to molecular PCR-based technologies. However, the application of the GeneXpert MTB/RIF assay to 
monitor treatment success is limited as mycobacterial DNA is a relatively stable molecule, which can remain in 
tissue months after bacterial sterilization [29] making DNA-based assays not widely applicable for treatment 
outcome measurements (Table 6.2). 
 
Conversely, detection systems that target RNA, a labile and dynamic molecule, correlate positively with bacterial 
survival. Molecular assays that measure either TB ribosomal 16S rRNA or messenger RNA have both been used 
successfully to monitor early treatment success, to quantify bacterial loads, and to measure declining bacterial 
numbers during chemotherapy [30-32] (Table 6.2). The positive correlation between RNA detection/abundance 
and the number of viable bacteria as measured conventionally using colony forming units highlights these RNA-
based assays as useful tools for preclinical drug discovery, and perhaps in the clinic for monitoring bacterial killing 
during TB chemotherapy. The advantages that these RNA-based detection assays have over conventional tests are 
that they are rapid and specific to M. tuberculosis because they do not depend on culturing mycobacteria or risk 
contamination; they also offer the potential to provide additional information about bacterial populations at the 
gene regulatory level. These culture-free methods provide meaningful information on treatment success by 
modeling the decline in bacterial load; correspondingly relapse may be identified before chemotherapy ends, 
providing an early opportunity to alter drug regimens accordingly. The application of global transcriptional 
profiling to TB bacilli derived from sputum before the start of chemotherapy [33] may enable RNA-based assays 
to be expanded to map gene expression signatures which predict drug efficacy by detecting drug tolerance or 
drug resistance patterns. In future, a panel of gene-specific assays may become useful markers for drug efficacy 
and treatment outcome. In addition, the use of global gene expression analyses as a tool in drug discovery from 
early preclinical research to clinical trials will enable new biomarkers to be characterized to evaluate drug 
efficacy, drug resistance, combinatory drug action and drug–drug interactions. 
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Table 6.2. Comparison of molecular-based assays for monitoring TB treatment success. 
 
 
 
Assay Molecule used for detection Pros and cons† Ref 
PCR-based molecular 
detection of nucleic acids 
(DNA, RNA) 
85B mRNA (fbpA ); 16S rRNA; 
IS6110 (DNA) 
mRNA signal was undetectable 
following two weeks of treatment; 
16S rRNA reduction was less than 
10-fold in the first 10 days; TB DNA 
was often present following 
successful treatment. 
[32] 
 
mRNA detection Isocitrate lyase (icl ); 
fibronectin-binding protein 
(fbpB); antigen 85B (fbpA); 
alpha-crystalline homologue 
(hspX); noncoding ribosomal 
promoter region (rrnA-P1) 
icl mRNA transcript was detectable 
after 2 months of chemotherapy; 
however, it was not consistent when 
compared with liquid and solid 
culture outcomes at the same time-
points. 
[31] 
Molecular Bacterial Load 
(MBL) assay 
16S rRNA Successful in quantifying bacterial 
load longitudinally, correlated well 
with liquid and solid culture data (0, 
3, 7, 14 and 56 days post-
chemotherapy). The incorporation of 
an internal control helped to account 
for performance inhibition. The limit 
of detection defined to be 100 
bacteria per ml of sputum. 
[30] 
GeneXpert MTB/RIF assay 
 
rpoB gene (DNA) A fully automated rapid and robust 
system that has been developed for 
the diagnosis of TB; its application 
for treatment monitoring is limited 
as it measures genomic DNA. 
 
[29] 
 
 
† An advantage of all molecular assays for treatment monitoring is that they are rapid in providing results; 
however, they often require specific expertise and they are more expensive compared to existing microbiological 
assays 
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Summary 
 
 There are a number of new chemical entities under clinical development for tuberculosis and prioritizing 
which of these will be tested, and in which drug combinations, in clinical trials remains a challenge. 
 Transcriptional profiling has been a useful tool for discovering the mechanism of action of novel 
inhibitors, as well as characterizing and modeling the different mycobacterial physiological states in vitro 
and in vivo. 
 Transcriptomic analyses may be useful in determining drug efficacy and in predicting the combinatory 
effects of multidrug regimens. 
 As assay sensitivity improves, the detection of M. tuberculosis RNA offers a promising new class of 
biomarkers that may monitor treatment efficacy during TB chemotherapy. 
 
 
Key terms 
 
Treatment outcome measurement: a procedure for evaluating whether a treatment regime is 
successful in combating disease. In tuberculosis (TB) treatment, 
the measured parameters might be bacterial load assayed by 
microscopy or growth in liquid or solid media, clinical disease, 
morbidity and mortality, rate of reactivation or protective 
immunity. Common assays include sputum smear microscopy, 
two month sputum culture conversion, and the recently 
introduced, serial sputum colony counts. 
 
TB combination therapy: the use of more than one drug taken simultaneously to treat 
tuberculosis. The main advantage of combination therapy is to 
reduce the emergence of antibiotic resistance while sterilising 
effectively. The World Health Organization recommends a 
standard therapy for drug-sensitive TB which includes four 
months of isoniazid, rifampicin, ethambutol and pyrazinamide, 
followed by two months of isoniazid and rifampicin. 
 
Transcriptional profiling: the measurement of the relative abundance of mRNA molecules 
from a population of cells that represents a snapshot of bacterial 
adaptations to the microenvironment. 
 
Early bactericidal activity (EBA):  monitoring the decline of the bacterial load in tubercular sputum 
after the start of chemotherapy; measured using microbiological 
methods. EBA studies are usually performed for up to two weeks 
following the beginning of treatment. 
 
Fractional Inhibitory Concentration 
Index (FICI): a measure of the effect of two drugs when compared with their 
single activities in vitro. The FICI is calculated by the sum of the 
ratios of the MIC for drug A in presence of drug B divided by the 
MIC of drug A, with the ratios of the MIC for drug B in presence 
of drug A divided by the MIC of drug B. FICI values ≤0.5 are 
classified as synergism, between 0.5 and 4.0 as no interaction or 
indifferent, and ≥4.0 as antagonism between drugs A and B. 
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